PRZOOM - /newswire/ -
Philadelphia, PA, United States, 2007/02/20 - Pierre Fabre Medicament and Zambon S.p.A. sign commercial agreement in Germany. Plexus Ventures, LLC represented Pierre Fabre in transaction.
Plexus Ventures, LLC, a global pharmaceutical business development firm, announced today the successful execution of an agreement between Pierre Fabre Medicament of France and Zambon S.p.A. of Italy. The deal, signed February 15, 2007, gives Pierre Fabre commercial rights for Zambon’s product portfolio in Germany.
The strategic partnership involves multiple products, including Panotile Cipro (anti-infective), Fluimicil (mucolytic), Monuril and Lorafem (antibiotics). In addition, Pierre Fabre will absorb Zambon’s specialist medical sales force in Germany to provide complete coverage of top physicians and pharmacists thus strengthening Pierre Fabre’s network in the country.
Pierre Fabre Medicament retained Plexus Ventures to assist with the company’s in-licensing and acquisition campaign in Germany. After careful evaluation of the client’s needs as well as a thorough assessment of the market, Plexus Ventures contacted more than 50 companies on behalf of Pierre Fabre and was involved in all aspects of the partnering process, from initial contacts through Due Diligence and final negotiations. The Plexus Ventures team was led by Mr. Pino Modica, Managing Partner, and success of the project was due in large part to the knowledge of the local marketplace brought by Senior Consultants Mr. Klaus Welzel in Frankfurt and Mr. Valerio Zoja in Milan.
"One of the main advantages Plexus Ventures brings to our clients is our strong international presence and extensive contacts within the most important markets in the Pharmaceutical industry," noted Pino Modica. "In this case, we were able to tap into our network of contacts within the industry to bring new opportunities to the table which were not publicly known. We are proud we were able to meet our client’s needs by finding an ideal partner and a deal structure which will benefit both parties in the long run."
Mr. Alain Benoit, Vice President of Corporate Licensing and Acquisitions for Pierre Fabre commented, "We knew that this was a difficult task and we are glad Plexus Ventures was able to meet the challenge and help us to achieve this important strategic objective of consolidating our presence in the German market."
Plexus Ventures (plexusventures.com), founded in 1990, provides strategic advice, business development and alliance management services to clients in the pharmaceutical, biotechnology and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Frankfurt, London, Los Angeles, Milan, Philadelphia, Tokyo and Warsaw, Plexus Ventures possesses the capabilities to effectively serve clients in the United States, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.